公开(公告)号：US20230002462A1

公开(公告)日：2023-01-05

申请号：US17886973

申请日：2022-08-12

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Heiko SCHUSTER ,  Daniel Johannes KOWALEWSKI ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  A61K35/17 ,  A61K39/00 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C12N5/0783 ,  C12Q1/6886

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220362364A1

公开(公告)日：2022-11-17

申请号：US17868368

申请日：2022-07-19

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Linus BACKERT ,  Heiko SCHUSTER ,  Daniel Johannes KOWALEWSKI ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: A61K39/00 ,  A61P35/00 ,  C07K7/06 ,  C07K16/28 ,  C07K16/30

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220280623A1

公开(公告)日：2022-09-08

申请号：US17743778

申请日：2022-05-13

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K16/28 ,  C07K14/705 ,  C07K7/08 ,  G16B25/10 ,  C12N9/12 ,  C07K7/06 ,  C07K16/40 ,  C07K14/71 ,  C07K14/47 ,  C12N15/115 ,  C12N9/02 ,  C12N5/0783 ,  C12Q1/6886 ,  C07K16/30 ,  G16B25/00 ,  C07K14/72 ,  C07K16/18 ,  C07K16/38 ,  G01N33/574 ,  C07K14/725 ,  C07K14/81

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220265794A1

公开(公告)日：2022-08-25

申请号：US17738418

申请日：2022-05-06

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K16/28 ,  C07K14/705 ,  C07K7/08 ,  G16B25/10 ,  C12N9/12 ,  C07K7/06 ,  C07K16/40 ,  C07K14/71 ,  C07K14/47 ,  C12N15/115 ,  C12N9/02 ,  C12N5/0783 ,  C12Q1/6886 ,  C07K16/30 ,  G16B25/00 ,  C07K14/72 ,  C07K16/18 ,  C07K16/38 ,  G01N33/574 ,  C07K14/725 ,  C07K14/81

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220194984A1

公开(公告)日：2022-06-23

申请号：US17691576

申请日：2022-03-10

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Steffen WALTER ,  Jens FRITSCHE ,  Colette SONG ,  Harpreet SINGH

IPC: C07K7/08 ,  C12N5/0783 ,  C12N9/64 ,  A61K38/17 ,  C07K7/06 ,  A61K39/00

Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an WIC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.

公开(公告)号：US20220112254A1

公开(公告)日：2022-04-14

申请号：US17561051

申请日：2021-12-23

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  C07K14/54 ,  G01N33/574 ,  C07K7/06 ,  C07K16/30 ,  C07K14/74 ,  C07K16/28 ,  C07K14/725 ,  A61K35/17 ,  C12N15/115 ,  C12N5/0783 ,  C12N15/10 ,  A61P35/00 ,  A61K39/00 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220106380A1

公开(公告)日：2022-04-07

申请号：US17554329

申请日：2021-12-17

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  C07K14/47 ,  G01N33/574 ,  C07K14/725 ,  C07K14/635 ,  C12N5/0783 ,  C12Q1/6886 ,  C07K16/28 ,  A61K35/17 ,  A61K39/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220054612A1

公开(公告)日：2022-02-24

申请号：US17519192

申请日：2021-11-04

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Colette SONG

IPC: A61K39/00 ,  A61P35/00 ,  C07K16/30 ,  C12N15/115 ,  C07K16/18 ,  C07K14/74 ,  G16B25/00 ,  C07K16/28 ,  G16B25/10 ,  A61K35/17 ,  C12N5/0783 ,  C07K14/47

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220002366A1

公开(公告)日：2022-01-06

申请号：US17471754

申请日：2021-09-10

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Annika SONNTAG ,  Daniel Johannes KOWALEWSKI ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH ,  Colette SONG

IPC: C07K14/47 ,  C07K14/725 ,  C07K14/74

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20210369826A1

公开(公告)日：2021-12-02

申请号：US17390583

申请日：2021-07-30

Applicant: Immatics Biotechnologies GmbH

Inventor： Sabrina KUTTRUFF-COQUI ,  Toni WEINSCHENK ,  Jens FRITSCHE ,  Steffen WALTER ,  Norbert HILF ,  Oliver SCHOOR ,  Colette SONG ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/705 ,  A61K35/17 ,  C07K7/06 ,  C07K7/08 ,  C07K14/74 ,  C07K16/28 ,  C12Q1/6886

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.